Latest news with #MerckKGaA
Malaysian Reserve
4 days ago
- Health
- Malaysian Reserve
Canadian Multiple Sclerosis Nurses Among Winners of International Nightingale Award 2025
Four Canadian nurses are among eleven global recipients of the International Nightingale award for excellence in MS nursing. The awards are presented by the International Organization of Multiple Sclerosis Nurses (IOMSN) with support from Merck KGaA, Darmstadt, Germany. MISSISSAUGA, ON, June 4, 2025 /CNW/ – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, is pleased to announce four Canadian nurses are among the recipients of the International Organization of Multiple Sclerosis Nurses (IOMSN) 2025 International Nightingale Award. The International Nightingale Award was launched in 2020 by IOMSN, with support from Merck KGaA, Darmstadt, Germany in celebration of the International Year of the Nurse and Midwife. 'As a company dedicated to advancing multiple sclerosis care for over 25 years, we recognize that MS nurses play a vital role in providing care and support to patients. We are excited to collaborate with the IOMSN in this initiative, which celebrates nursing professionals and supports impactful projects that enhance patient outcomes,' said Javed Alam, Managing Director of EMD Serono Canada. Having Canadian recipients of the International Nightingale Award recognizes the significance of MS nurse contributions to patient management and highlights the leadership role that Canadian nurses play on a global level. Shantha George, a community MS nurse practitioner in Edmonton, will receive $5,000 USD to support her Fight Back: Living Well with MS Program, an initiative that focuses on lifestyle management for mental health where patients learn tips to manage anxiety and depression including breathing techniques, drumming and yoga. Stephanie McLeod, a nurse practitioner at the Alberta Neurologic Centre in Calgary will receive $5,000 USD to support the development of a new program to enhance patient and family education, empowering those affected with MS with the knowledge and support they need. Lou-Anne Robertson, a registered nurse at the Central Alberta Multiple Sclerosis Clinic in Red Deer will receive $5,000 USD to support her efforts to raise awareness about the benefits of MS nurse certification for patient care and professional growth. Trudy Campbell, a nurse practitioner at the Halifax MS Clinic, Nova Scotia Health will receive $5,000 USD to support her work on evidence informed, holistic care pathways related to health promotion to support healthy aging for persons with MS. 'Since 2020, IOMSN, EMD Serono and Merck KGaA Darmstadt, Germany have proudly celebrated 'The Lady with the Lamp', Florence Nightingale, who is a symbol of compassion, data-driven care, and nursing excellence. The IOMSN Nightingale Awards empower nurses to bring bold ideas to life, driving meaningful change for those living with MS' said Bonnie Blain, President of the IOMSN. ' These awards not only recognize achievement but also inspire continued innovation and leadership in nursing. We are thrilled to partner again with Merck KGaA Darmstadt, Germany to present the 2025 International Nightingale Awards. I am honored to celebrate these Canadian Nightingale Recipients whose impactful work has the potential to improve the lives of their patients and resonate across their communities.' The International Nightingale Award was awarded to eleven eligible candidates who live and work in countries outside of the United States. Each will receive funding of up to 5000 US Dollars for current projects that require ongoing and/or additional funding for the growth of the program; proposed time-limited projects; personal activities that will support the professional growth and development of an MS nursing professional; and/or nursing research in MS or a related field. About Multiple SclerosisMultiple Sclerosis (MS) is a degenerative autoimmune disease in which the myelin sheath around the nerves in the brain and spinal cord are inflamed and often damaged. It is estimated that approximately 2.3 million people have MS worldwide. Canada has one of the highest rates of MS in the world with one in 385 people living with the disease. While symptoms vary, the most common symptoms of MS include extreme fatigue, lack of coordination, weakness, tingling, impaired sensation, vision problems, bladder problems, cognitive impairment and mood changes. The relapsing forms of MS are the most common type at the time of diagnosis. About the International Organization of Multiple Sclerosis Nurses (IOMSN)Founded on May 30, 1997, International Organization of Multiple Sclerosis Nurses (IOMSN) is the first and only international organization focusing solely on the needs and goals of professional nurses, anywhere in the world, who care for people with multiple sclerosis. Mentoring, educating, networking, sharing – the IOMSN supports nurses in their continuing effort to offer hope. The mission of the IOMSN is the establishment and perpetuation of a specialized branch of nursing in multiple sclerosis; to establish standards of nursing care in multiple sclerosis; to support multiple sclerosis nursing research; and to educate the health care community about multiple sclerosis; and to disseminate this knowledge throughout the world. The ultimate goal of the IOMSN is to improve the lives of all those persons affected by multiple sclerosis through the provision of appropriate healthcare services and to make hope happen! About EMD Serono, CanadaEMD Serono, Canada, is the Canadian biopharmaceutical business of Merck KGaA, Darmstadt, Germany. EMD Serono, Canada has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono, Canada has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono, Canada has more than 100 employees across Canada with headquarters in Mississauga, Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion in 66 company holds the global rights to the name and trademark 'Merck' internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Cision Canada
4 days ago
- Business
- Cision Canada
Canadian Multiple Sclerosis Nurses Among Winners of International Nightingale Award 2025
Four Canadian nurses are among eleven global recipients of the International Nightingale award for excellence in MS nursing. The awards are presented by the International Organization of Multiple Sclerosis Nurses (IOMSN) with support from Merck KGaA, Darmstadt, Germany. MISSISSAUGA, ON, June 4, 2025 /CNW/ - EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, is pleased to announce four Canadian nurses are among the recipients of the International Organization of Multiple Sclerosis Nurses (IOMSN) 2025 International Nightingale Award. The International Nightingale Award was launched in 2020 by IOMSN, with support from Merck KGaA, Darmstadt, Germany in celebration of the International Year of the Nurse and Midwife. "As a company dedicated to advancing multiple sclerosis care for over 25 years, we recognize that MS nurses play a vital role in providing care and support to patients. We are excited to collaborate with the IOMSN in this initiative, which celebrates nursing professionals and supports impactful projects that enhance patient outcomes," said Javed Alam, Managing Director of EMD Serono Canada. Having Canadian recipients of the International Nightingale Award recognizes the significance of MS nurse contributions to patient management and highlights the leadership role that Canadian nurses play on a global level. Shantha George, a community MS nurse practitioner in Edmonton, will receive $5,000 USD to support her Fight Back: Living Well with MS Program, an initiative that focuses on lifestyle management for mental health where patients learn tips to manage anxiety and depression including breathing techniques, drumming and yoga. Stephanie McLeod, a nurse practitioner at the Alberta Neurologic Centre in Calgary will receive $5,000 USD to support the development of a new program to enhance patient and family education, empowering those affected with MS with the knowledge and support they need. Lou-Anne Robertson, a registered nurse at the Central Alberta Multiple Sclerosis Clinic in Red Deer will receive $5,000 USD to support her efforts to raise awareness about the benefits of MS nurse certification for patient care and professional growth. Trudy Campbell, a nurse practitioner at the Halifax MS Clinic, Nova Scotia Health will receive $5,000 USD to support her work on evidence informed, holistic care pathways related to health promotion to support healthy aging for persons with MS. "Since 2020, IOMSN, EMD Serono and Merck KGaA Darmstadt, Germany have proudly celebrated 'The Lady with the Lamp', Florence Nightingale, who is a symbol of compassion, data-driven care, and nursing excellence. The IOMSN Nightingale Awards empower nurses to bring bold ideas to life, driving meaningful change for those living with MS" said Bonnie Blain, President of the IOMSN. " These awards not only recognize achievement but also inspire continued innovation and leadership in nursing. We are thrilled to partner again with Merck KGaA Darmstadt, Germany to present the 2025 International Nightingale Awards. I am honored to celebrate these Canadian Nightingale Recipients whose impactful work has the potential to improve the lives of their patients and resonate across their communities." The International Nightingale Award was awarded to eleven eligible candidates who live and work in countries outside of the United States. Each will receive funding of up to 5000 US Dollars for current projects that require ongoing and/or additional funding for the growth of the program; proposed time-limited projects; personal activities that will support the professional growth and development of an MS nursing professional; and/or nursing research in MS or a related field. About Multiple Sclerosis Multiple Sclerosis (MS) is a degenerative autoimmune disease in which the myelin sheath around the nerves in the brain and spinal cord are inflamed and often damaged. It is estimated that approximately 2.3 million people have MS worldwide. Canada has one of the highest rates of MS in the world with one in 385 people living with the disease. While symptoms vary, the most common symptoms of MS include extreme fatigue, lack of coordination, weakness, tingling, impaired sensation, vision problems, bladder problems, cognitive impairment and mood changes. The relapsing forms of MS are the most common type at the time of diagnosis. About the International Organization of Multiple Sclerosis Nurses (IOMSN) Founded on May 30, 1997, International Organization of Multiple Sclerosis Nurses (IOMSN) is the first and only international organization focusing solely on the needs and goals of professional nurses, anywhere in the world, who care for people with multiple sclerosis. Mentoring, educating, networking, sharing - the IOMSN supports nurses in their continuing effort to offer hope. The mission of the IOMSN is the establishment and perpetuation of a specialized branch of nursing in multiple sclerosis; to establish standards of nursing care in multiple sclerosis; to support multiple sclerosis nursing research; and to educate the health care community about multiple sclerosis; and to disseminate this knowledge throughout the world. The ultimate goal of the IOMSN is to improve the lives of all those persons affected by multiple sclerosis through the provision of appropriate healthcare services and to make hope happen! About EMD Serono, Canada EMD Serono, Canada, is the Canadian biopharmaceutical business of Merck KGaA, Darmstadt, Germany. EMD Serono, Canada has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono, Canada has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono, Canada has more than 100 employees across Canada with headquarters in Mississauga, Ontario. About Merck KGaA, Darmstadt, Germany Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion in 66 countries. The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Yahoo
4 days ago
- General
- Yahoo
Canadian Multiple Sclerosis Nurses Among Winners of International Nightingale Award 2025
Four Canadian nurses are among eleven global recipients of the International Nightingale award for excellence in MS nursing. The awards are presented by the International Organization of Multiple Sclerosis Nurses (IOMSN) with support from Merck KGaA, Darmstadt, Germany. MISSISSAUGA, ON, June 4, 2025 /CNW/ - EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, is pleased to announce four Canadian nurses are among the recipients of the International Organization of Multiple Sclerosis Nurses (IOMSN) 2025 International Nightingale Award. The International Nightingale Award was launched in 2020 by IOMSN, with support from Merck KGaA, Darmstadt, Germany in celebration of the International Year of the Nurse and Midwife. "As a company dedicated to advancing multiple sclerosis care for over 25 years, we recognize that MS nurses play a vital role in providing care and support to patients. We are excited to collaborate with the IOMSN in this initiative, which celebrates nursing professionals and supports impactful projects that enhance patient outcomes," said Javed Alam, Managing Director of EMD Serono Canada. Having Canadian recipients of the International Nightingale Award recognizes the significance of MS nurse contributions to patient management and highlights the leadership role that Canadian nurses play on a global level. Shantha George, a community MS nurse practitioner in Edmonton, will receive $5,000 USD to support her Fight Back: Living Well with MS Program, an initiative that focuses on lifestyle management for mental health where patients learn tips to manage anxiety and depression including breathing techniques, drumming and yoga. Stephanie McLeod, a nurse practitioner at the Alberta Neurologic Centre in Calgary will receive $5,000 USD to support the development of a new program to enhance patient and family education, empowering those affected with MS with the knowledge and support they need. Lou-Anne Robertson, a registered nurse at the Central Alberta Multiple Sclerosis Clinic in Red Deer will receive $5,000 USD to support her efforts to raise awareness about the benefits of MS nurse certification for patient care and professional growth. Trudy Campbell, a nurse practitioner at the Halifax MS Clinic, Nova Scotia Health will receive $5,000 USD to support her work on evidence informed, holistic care pathways related to health promotion to support healthy aging for persons with MS. "Since 2020, IOMSN, EMD Serono and Merck KGaA Darmstadt, Germany have proudly celebrated 'The Lady with the Lamp', Florence Nightingale, who is a symbol of compassion, data-driven care, and nursing excellence. The IOMSN Nightingale Awards empower nurses to bring bold ideas to life, driving meaningful change for those living with MS" said Bonnie Blain, President of the IOMSN. " These awards not only recognize achievement but also inspire continued innovation and leadership in nursing. We are thrilled to partner again with Merck KGaA Darmstadt, Germany to present the 2025 International Nightingale Awards. I am honored to celebrate these Canadian Nightingale Recipients whose impactful work has the potential to improve the lives of their patients and resonate across their communities." The International Nightingale Award was awarded to eleven eligible candidates who live and work in countries outside of the United States. Each will receive funding of up to 5000 US Dollars for current projects that require ongoing and/or additional funding for the growth of the program; proposed time-limited projects; personal activities that will support the professional growth and development of an MS nursing professional; and/or nursing research in MS or a related field. About Multiple SclerosisMultiple Sclerosis (MS) is a degenerative autoimmune disease in which the myelin sheath around the nerves in the brain and spinal cord are inflamed and often damaged. It is estimated that approximately 2.3 million people have MS worldwide. Canada has one of the highest rates of MS in the world with one in 385 people living with the disease. While symptoms vary, the most common symptoms of MS include extreme fatigue, lack of coordination, weakness, tingling, impaired sensation, vision problems, bladder problems, cognitive impairment and mood changes. The relapsing forms of MS are the most common type at the time of diagnosis. About the International Organization of Multiple Sclerosis Nurses (IOMSN)Founded on May 30, 1997, International Organization of Multiple Sclerosis Nurses (IOMSN) is the first and only international organization focusing solely on the needs and goals of professional nurses, anywhere in the world, who care for people with multiple sclerosis. Mentoring, educating, networking, sharing - the IOMSN supports nurses in their continuing effort to offer hope. The mission of the IOMSN is the establishment and perpetuation of a specialized branch of nursing in multiple sclerosis; to establish standards of nursing care in multiple sclerosis; to support multiple sclerosis nursing research; and to educate the health care community about multiple sclerosis; and to disseminate this knowledge throughout the world. The ultimate goal of the IOMSN is to improve the lives of all those persons affected by multiple sclerosis through the provision of appropriate healthcare services and to make hope happen! About EMD Serono, CanadaEMD Serono, Canada, is the Canadian biopharmaceutical business of Merck KGaA, Darmstadt, Germany. EMD Serono, Canada has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono, Canada has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono, Canada has more than 100 employees across Canada with headquarters in Mississauga, Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion in 66 company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. SOURCE EMD Serono Canada View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
CRISPR Market Research and Competitive Landscape Report 2025 - Global Forecast to 2030: Rising Adoption in Research and Therapy Drives Growth with Thermo Fisher Scientific and Merck Leading
Growth is fueled by increased adoption in research and industry, advancements in CRISPR tools, and rising investments in biotechnology. Key applications include drug discovery and gene therapy, with pharmaceutical and biotech companies dominating the market. North America leads the sector, driven by innovative research and strong investment. Amidst this expansion, companies like Thermo Fisher Scientific and Merck KGaA emerge as market leaders, shaping the competitive landscape with new developments and collaborations. CRISPR Market Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "CRISPR Market by Offering [Product (Kits, Enzymes, Libraries), Service (gRNA Synthesis, Cell Line Development, Screening, Validation)], Application (Drug Discovery, Development, Agriculture) Competitive Landscape, Company Profiles -Global Forecast to 2030" has been added to offering. The global CRISPR market is set to expand from USD 3.21 billion in 2025 to USD 5.47 billion by 2030, registering a robust CAGR of 11.2% The report presents an analysis of market drivers, focusing on the rising demand for CRISPR-based therapies and ongoing technological advancements. It identifies key opportunities for CRISPR in areas such as vaccines and genetic disease treatments. A comprehensive evaluation of market shares and growth strategies of leading companies is included, along with an overview of challenges, particularly regulatory hurdles, that affect market progression. Growth is fueled by the technology's expanding use in research, clinical, and industrial applications, supported by increased investments in biotechnology R&D and the growing prevalence of genetic disorders. As CRISPR tools and delivery systems improve, and regulatory frameworks become more supportive, the integration of CRISPR into research and therapeutic pipelines accelerates. Leading companies include Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, GenScript, Takara Bio, Creative Biogene, Fujian SunyBiotech, Caribou Biosciences, Lonza Group, Danaher Corporation, among others. Products Dominated the Market in 2024 The CRISPR market is divided into products and services. The products segment, which includes CRISPR kits & enzymes and CRISPR libraries, leads the market. These products are essential in academic, clinical, and industrial research for genome editing and therapeutic development. This segment's growth is driven by the demand for standardized and innovative CRISPR products. Drug Discovery & Development: A Fast-Growing Application Segment Within applications, drug discovery & development is the largest and fastest-growing segment, leveraging CRISPR to find gene-disease links and streamline drug functions. This reduces timelines and increases success probabilities. Pharmaceutical and biotechnology firms are pivotal in incorporating CRISPR for personalized medicine and functional genomics, further driving the technology's adoption. Pharmaceutical & Biotechnology Companies' Market Dominance in 2024 These companies led the CRISPR products market in 2024, thanks to increased investment in cell and gene therapies, and the need for precise genetic tools. Their financial strength allows them to implement advanced CRISPR technologies effectively, bolstering their market position. North America's Leadership in the CRISPR Market North America, with its prominent research institutions and substantial biotech investments, captured the largest CRISPR market share in 2024. The region's emphasis on medical research and personalized medicine offers it a competitive edge. European markets, especially in Germany, the UK, and France, are also seeing robust growth due to heightened R&D activity. Key Attributes: Report Attribute Details No. of Pages 267 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $3.21 Billion Forecasted Market Value (USD) by 2030 $5.47 Billion Compound Annual Growth Rate 11.2% Regions Covered Global Market Dynamics Drivers Growing Demand for Crispr-Based Gene Therapies Advancements in Crispr Technology Growing Government and Private Investments and Funding for Crispr Technology Restraints Technical Challenges Associated With Crispr Technology Opportunities Development of New Vaccines and Treatments for Genetic Diseases Expanding Industrial and Agricultural Applications of Crispr Challenges Regulatory Hurdles for Crispr Advancements Technology Analysis Key Technologies Crispr-Cas Systems Grna Design & Optimization High-Throughput Crispr Screening Complementary Technologies Synthetic Biology Single-Cell Genomics Next-Generation Sequencing Adjacent Technologies Stem Cell Engineering Synthetic Dna & Gene Synthesis Microfluidics Company Profiles Thermo Fisher Scientific Inc. Merck Kgaa Agilent Technologies, Inc. Genscript Revvity Lonza Danaher Corporation Takara Bio Inc. Creative Biogene Fujian Sunybiotech Co., Ltd. Editco Caribou Biosciences, Inc. Hera Biolabs Origene Technologies, Inc. Cellecta, Inc. Mammoth Biosciences, Inc. Applied Stemcell New England Biolabs Toolgen, Inc. Genecopoeia, Inc. Twist Bioscience Synthego Egenesis Inscripta, Inc. Precision Biosciences For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment CRISPR Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
CRISPR Market Research and Competitive Landscape Report 2025 - Global Forecast to 2030: Rising Adoption in Research and Therapy Drives Growth with Thermo Fisher Scientific and Merck Leading
Growth is fueled by increased adoption in research and industry, advancements in CRISPR tools, and rising investments in biotechnology. Key applications include drug discovery and gene therapy, with pharmaceutical and biotech companies dominating the market. North America leads the sector, driven by innovative research and strong investment. Amidst this expansion, companies like Thermo Fisher Scientific and Merck KGaA emerge as market leaders, shaping the competitive landscape with new developments and collaborations. CRISPR Market Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "CRISPR Market by Offering [Product (Kits, Enzymes, Libraries), Service (gRNA Synthesis, Cell Line Development, Screening, Validation)], Application (Drug Discovery, Development, Agriculture) Competitive Landscape, Company Profiles -Global Forecast to 2030" has been added to offering. The global CRISPR market is set to expand from USD 3.21 billion in 2025 to USD 5.47 billion by 2030, registering a robust CAGR of 11.2% The report presents an analysis of market drivers, focusing on the rising demand for CRISPR-based therapies and ongoing technological advancements. It identifies key opportunities for CRISPR in areas such as vaccines and genetic disease treatments. A comprehensive evaluation of market shares and growth strategies of leading companies is included, along with an overview of challenges, particularly regulatory hurdles, that affect market progression. Growth is fueled by the technology's expanding use in research, clinical, and industrial applications, supported by increased investments in biotechnology R&D and the growing prevalence of genetic disorders. As CRISPR tools and delivery systems improve, and regulatory frameworks become more supportive, the integration of CRISPR into research and therapeutic pipelines accelerates. Leading companies include Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, GenScript, Takara Bio, Creative Biogene, Fujian SunyBiotech, Caribou Biosciences, Lonza Group, Danaher Corporation, among others. Products Dominated the Market in 2024 The CRISPR market is divided into products and services. The products segment, which includes CRISPR kits & enzymes and CRISPR libraries, leads the market. These products are essential in academic, clinical, and industrial research for genome editing and therapeutic development. This segment's growth is driven by the demand for standardized and innovative CRISPR products. Drug Discovery & Development: A Fast-Growing Application Segment Within applications, drug discovery & development is the largest and fastest-growing segment, leveraging CRISPR to find gene-disease links and streamline drug functions. This reduces timelines and increases success probabilities. Pharmaceutical and biotechnology firms are pivotal in incorporating CRISPR for personalized medicine and functional genomics, further driving the technology's adoption. Pharmaceutical & Biotechnology Companies' Market Dominance in 2024 These companies led the CRISPR products market in 2024, thanks to increased investment in cell and gene therapies, and the need for precise genetic tools. Their financial strength allows them to implement advanced CRISPR technologies effectively, bolstering their market position. North America's Leadership in the CRISPR Market North America, with its prominent research institutions and substantial biotech investments, captured the largest CRISPR market share in 2024. The region's emphasis on medical research and personalized medicine offers it a competitive edge. European markets, especially in Germany, the UK, and France, are also seeing robust growth due to heightened R&D activity. Key Attributes: Report Attribute Details No. of Pages 267 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $3.21 Billion Forecasted Market Value (USD) by 2030 $5.47 Billion Compound Annual Growth Rate 11.2% Regions Covered Global Market Dynamics Drivers Growing Demand for Crispr-Based Gene Therapies Advancements in Crispr Technology Growing Government and Private Investments and Funding for Crispr Technology Restraints Technical Challenges Associated With Crispr Technology Opportunities Development of New Vaccines and Treatments for Genetic Diseases Expanding Industrial and Agricultural Applications of Crispr Challenges Regulatory Hurdles for Crispr Advancements Technology Analysis Key Technologies Crispr-Cas Systems Grna Design & Optimization High-Throughput Crispr Screening Complementary Technologies Synthetic Biology Single-Cell Genomics Next-Generation Sequencing Adjacent Technologies Stem Cell Engineering Synthetic Dna & Gene Synthesis Microfluidics Company Profiles Thermo Fisher Scientific Inc. Merck Kgaa Agilent Technologies, Inc. Genscript Revvity Lonza Danaher Corporation Takara Bio Inc. Creative Biogene Fujian Sunybiotech Co., Ltd. Editco Caribou Biosciences, Inc. Hera Biolabs Origene Technologies, Inc. Cellecta, Inc. Mammoth Biosciences, Inc. Applied Stemcell New England Biolabs Toolgen, Inc. Genecopoeia, Inc. Twist Bioscience Synthego Egenesis Inscripta, Inc. Precision Biosciences For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment CRISPR Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
